Quarterly report pursuant to Section 13 or 15(d)

Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details)

v3.22.1
Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Faculty
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Research and development expense $ 9,170,000 $ 6,556,000  
License Agreement      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Obligation to be paid $ 2,000,000    
Payment term 3 years    
Payment commencement date 2018-08    
License maintenance fee $ 10,000    
Total milestone payments 21,000,000    
Amounts due to agreement 0    
Sponsored Research Agreements | Penn      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Obligation to be paid $ 12,483,000   $ 400,000
Number of faculty member | Faculty 2    
Funding term end date 2022-11    
Cost incurred $ 10,831,000    
Research and development expense 900,000 837,000  
Sponsored Research Agreements | Penn | Prepaid Expenses and Other Current Assets      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Advance payments 173,000   346,000
Sponsored Research Agreements | Penn | Accrued and Other Current Liabilities      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Obligation to be paid 764,000   36,000
Master Translational Research Services Agreement      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Research and development expense 635,000 395,000  
Remaining research and development expense to be incurred 1,360,000    
Subscription and Technology Transfer Agreement      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Research and development expense $ 0 $ 150,000  
Oxford Biomedica      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Obligation to be paid     4,000,000
Research and development expense     $ 1,100,000